will compounding pharmacies have to stop making tirzepatide FDA says can keep weight-loss med tirzepatide, for now The Safety of Compounding Pharmacies

These follow-on patents, also known as secondary patents, mainly consist of formulations, combinations with other drugs, methods of treating different indications that were alreadydisclosed in the main compound patents, and drug delivery devices

Tirzepatide is a cutting-edge prescription medication originally developed for type 2 diabetes and now used off-label for medical weight loss

Hormonal fluctuations influence female tirzepatide response more than male outcomes

It was easy to use and store

Laboratory monitoring, including hemoglobin A1c, should be performed quarterly if therapy has changed or glycemic targets are not being met, and twice yearly if stable at goal

Financial commitment Running both compounds simultaneously involves significant ongoing expense